Form 990 for tax year 2024

Totals

Total revenue

$0

Total expenses

$275,738

Contributions and grants received

$0

Grants paid

$0

Program service revenue

$0

Investment income

$0

Other revenue

$0

Total assets, end of year

$0

Total liabilities, end of year

$0

Net assets or fund balances, end of year

$0

Program services expenses (Part IX)

$275,738

Management and general expenses

$0

Fundraising expenses

$0

Program service expenses (Part III)

$275,738

Program services were 100.0% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2024

• Dana-Farber/Children's Hospital Cancer Care, Inc. ("DF/CHCC") is a Massachusetts charitable corporation organized on December 14, 2000, whose members are The Children's Hospital Corporation ("Children's") and Dana-Farber Cancer Institute, Inc. ("Dana-Farber"). Its primary purpose is to oversee, coordinate and support the Pediatric Oncology Program (the "Joint Program"). It also, formalizes the pediatric oncology partnership that has existed between Dana-Farber and Boston Children's since 1947.The Joint Program, which is the largest pediatric oncology program in New England and one of the most active in the country, offers the combined expertise of both a world-class cancer center and an internationally renowned children's hospital. Neighboring institutes connected by pedestrian bridges, Dana-Farber Cancer Institute and Boston Children's Hospital work together to offer seamless, integrated care for children with all types of cancer and blood disorders including the rarest and most complex cases. Through our joint partnership, Dana-Farber/Boston Children's offers more specialists, more treatment options, and more clinical trials than almost any other pediatric center treating cancer and blood disorders in the world.Our Expertise in Treating Pediatric Cancer and Blood Disorders: Our hematologists and oncologists are among the world leaders in their respective specialties; many have pioneered treatments that have been adopted by medical communities around the globe. Our doctors also collaborate with teams of expert subspecialists to provide truly comprehensive care for our patients. Innovative Approaches:Our history of research and innovation has resulted in many of the diagnostic and therapeutic techniques currently used around the world to treat cancer and blood disorders. Today, we continue to stand among the world's leaders in many innovative approaches.Our research, clinical trials, and state-of-the art treatment facilities allow our care teams to provide the safest and most effective care possible.Some of our innovative approaches include:- The Advancing Childhood Cancer Therapies (ACCT) Clinic offers clinical trials for relapsed and refractory cancer. CAR T-cell therapy is a promising new treatment for some of the most challenging cases we face in pediatric leukemia and lymphoma. - Gene therapy delivers DNA into a patient's cells to replace faulty or missing genes or to add new genes in an attempt to cure a disease or make changes so the body is better able to fight off disease. - Immunotherapy is the treatment of disease by inducing, enhancing, or suppressing an immune response. Cancer immunotherapy attempts to stimulate the immune system to reject or destroy tumors.- MIBG therapy is a special treatment for children with refractory or relapsed neuroblastoma. We are one of only a handful of centers in the United States equipped for this type of treatment. - Our Pediatric Cancer Genetic Risk Program provides cancer risk assessment and comprehensive recommendations for managing cancer risk. We also conduct research into many aspects of cancer risk and its management.- Precision medicine allows doctors to tailor treatment to the specific genetic characteristics of a patient's cancer. Dana-Farber/Boston Children's is involved in one of the country's most comprehensive precision cancer medicine initiatives.Conditions we treat: Utilizing proven treatment protocols and innovative therapies, Dana-Farber/Boston Children's Cancer and Blood Disorders Center treats over 100 forms of cancer and blood disorders in children and young adults, including:- Blood Disorders - Our Blood Disorders Center provides comprehensive care for a wide range of non-malignant blood disorders including anemia, hemophilia, myelodysplastic syndrome, sickle cell disease and thalassemia. - Brain Tumors - The specialists in our Brain Tumor Center have the expertise to treat a wide range of malignant brain tumors, including atypical teratoid rhabdoid tumor (AT/RT), diffuse pontine glioma and germ cell tumors of the brain.- Leukemia, Lymphoma, and Histiocytosis - The specialists in our Hematologic Malignancies Center are world leaders in the treatment of pediatric leukemia and lymphoma as well as the primary types of histiocytosis.- Solid Tumors - Our Solid Tumor Center provides advanced treatment, including surgery, for a wide range of solid tumors, including bone tumors like osteosarcoma, soft tissue tumors, neuroblastoma, kidney tumors and liver tumors. - Other Conditions We Treat - The specialists at Dana-Farber/Boston Children's also participate in the care of children and teens with a variety of conditions that do not come under the umbrella of cancers or blood disorders. These other conditions include genetic immunodeficiencies, metabolic disorders, vascular anomalies, and cardiovascular diseases such as pulmonary hypertension and pulmonary vein stenosis.

  Expenses $275,738

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

No itemized grants to organizations on this return.

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

• Children's Hospital Corporation

  501(c)(3) · Pediatric healthcare, education and research hospital · MA

  Directly controlled by Children's Medical Center Corporation

• Dana-Farber Cancer Institute Inc

  501(c)(3) · Cancer care research · MA

Provenance

Return type

form_990

Tax year

2024

Filed

13 August 2026

IRS schema version

2024v5.5

Source object

202642269349303604

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.